Skip to content

AML-ALL

US Focus Meeting 2026

📍 Estancia La Jolla Hotel, 9700 N Torrey Pines Rd, La Jolla, CA 92037


🗓️ July 9 - 11, 2026

Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the US AML-ALL Focus Meeting 2026, to be held on July 9 - 11, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing AML-ALL research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

 

Co-Chairs of AML-ALL Focus Meeting 2026:

Naval-Daver

Naval Daver, MD
MD Anderson Cancer Center, Houston, TX


Elias-Jabbour

Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX


Thanks to Our Supporters

Platinum

Daiichi-Sankyo

Gold

Abbvie_Logo
amgen
kura
servier
syndax

Silver

astellas
Autolus_square
Rigel_Logo
logo_menarini
Sumitomo-Logo-NEW
Takeda_Logo
quetzal-tx

Additional support provided by Johnson & Johnson
in the form of an educational grant

Agenda & Faculty

July 9, 2026 | Day 1  

01:00 PM     Registration Opens

Session I: Focus on Chronic Leukemia - Updates 2026
Moderated by:

Hagop-Kantarjian-1

Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX


02:00 PM     Updates on CML
Hagop-Kantarjian-1
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:20 PM      Updates on CLL
Nitin-Jain
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
02:40 PM      Panel Discussion
03:10 PM      Coffee Break & Networking

Session II: Focus on MDS and BPDCN - Updates 2026
Moderated by:

Naval-Daver

Naval Daver, MD
MD Anderson Cancer Center, Houston, TX


03:30 PM      Updates on MDS
Rami-Komrokji
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
03:50 PM      Updates on BPDCN
Naveen-Pemmaraju
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
04:10 PM     Beyond Genomics: Redefining Risk in AML
Hussein-Abbas
Hussein Abbas, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM      Panel discussion & Take-home Points from Day 1
05:00 PM      Adjourn

July 10, 2026 | Day 2  

08:00 AM      Registration Opens

Session III: Toward a Better Stratification and Chemotherapy-Free Regimens
Moderated by:

Elias-Jabbour

Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX


09:00 AM     Molecular Risk Stratification in ALL
Charles Mullighan-1
Charles Mullighan, MD
St. Jude Children’s Research Hospital, Memphis, TN
09:15 AM      How I Treat Ph-Positive ALL
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:30 AM      MRD in Ph-positive ALL BCR:ABL1 vs NGS for IgR
Nicholas-Short
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
09:45 AM      Older ALL
Matthew-Wieduwilt-1
Matthew Wieduwilt, MD
Wake Forest University School of Medicine, Winston-Salem, NC
10:00 AM      Panel Discussion
10:30 AM      Coffee Break & Networking

Session IV: Molecular Stratification of AML and a Focus on Menin Therapeutics
Moderated by:

Courtney-Dinardo

Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX

10:50 AM      Genetic and Molecular Diagnostics in AML
Sanam-Loghavi-1
Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX
11:05 AM      Frontline Fit NPM1 Mutated AML: What Are the Current Data and Where Do We See This Evolving in the Near Future
Amer-Zeidan
Amer Zeidan, MD
Yale School of Medicine, New Haven, CT
11:20 AM      Menin Inhibitors in R/R AML: Updates on Single Agent Efficacy, Safety, Resistance and Role of Second Generation Menin Inhibitors
Justin-Watts
Justin Watts, MD
University of Miami Miller School of Medicine, Miami, FL
11:35 AM      Moving Beyond Single-Agent Menin Inhibitors: Emerging Data and Optimization of Menin Inhibitor Combos
Joshua-Zeidner-1
Joshua Zeidner, MD
UNC School of Medicine, Chapel Hill, NC
11:50 AM      Panel Discussion
12:20 PM      Industry Supported Independent Expert Discussion

01:05 PM      Lunch Break & Networking

Session V: Optimizing Frontline Therapy in Ph-negative ALL
Moderated by:

Aaron-Logan-1

Aaron Logan, MD
UCSF Health, San Francisco, CA

 

01:55 PM      Management of ALL: Closing the Gap Between Centers of Excellence and Underserved Communities
Lori-Muffly
Lori Muffly, MD
Stanford Medicine, CA
02:10 PM      MRD Eradication and When Allogeneic Transplant is Still Needed
Aaron-Logan-1
Aaron Logan, MD
UCSF Health, San Francisco, CA
02:25 PM      How Much Chemotherapy is Still Needed in Newly Diagnosed Adults With ALL
Hagop-Kantarjian-1
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:40 PM     T-ALL: New directions for the overlooked subset
Wendy-Stock
Wendy Stock, MD
The University of Chicago Medicine, Chicago, IL
02:55 PM     Panel Discussion
03:25 PM     Coffee Break & Networking

Session VI: Optimizing Frontline AML Treatment - Focus on Less Intensive Therapies
Moderated by:

Naval-Daver

Naval Daver, MD
MD Anderson Cancer Center, Houston, TX

 

03:45 PM      AZA+VEN for all – or Not Really?
Amir-Fathi-1
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA
04:00 PM      Triplets in AML: Are We There Yet and If So for Which Ones Are We Really There?
Naval-Daver
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
04:15 PM      How do I use IDH Inhibitors in Frontline and R/R AML
Courtney-Dinardo
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM      Optimizing Measurement of MRD in AML and How Should We Use MRD in Guiding the Treatment of AML
Christopher-Hourigan
Christopher Hourigan, DM, DPhil, FRCP
Virginia Tech FBRI Cancer Research Center, Washington, D.C.
04:45 PM      Panel Discussion
05:15 PM      Special Lecture: AML 2026 Future Directions
Hagop-Kantarjian-1
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
05:30 PM      Questions & Adjourn

July 11, 2026 | Day 3  

08:30 AM      Registration Opens

Session VII: Novel Bi-specifics and Optimizing CAR-T Strategies
Moderated by:

Bijal-Shah

Bijal Shah, MD
Moffitt Cancer Center, Tampa, FL

 

09:00 AM      Novel Agents in R/R ALL: SQ Blina
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:15 AM      Other Bispecifics and ADC
Ibrahim-Aldoss
Ibrahim Aldoss, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
09:30 AM      How to Optimize Outcomes Post CAR T
Bijal-Shah
Bijal Shah, MD
Moffitt Cancer Center, Tampa, FL
09:45 AM      Optimizing Maintenance Approaches in Non-Transplanted Patients With ALL
Jae-Park
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
10:00 AM      Can CAR T replace allo-SCT? Where and when?
nitin jain-1
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
10:15 AM      Panel Discussion
10:45 AM      Coffee Break & Networking

Session VIII: Optimizing Frontline AML Treatment - Focus on Intensive Chemotherapies
Moderated by:

Tapan-Kadia

Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX

 

11:05 AM      Genomic Strategies to Guide the Choice of Intensive Treatment Strategies in NonFLT3m AML
Eunice-Wang
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY
11:20 AM      Frontline Treatment of FLT3-ITD Mutated AML – Where are we Headed
Alexander-Perl
Alexander Perl, MD
University of Pennsylvania, Philadelphia, PA
11:35 AM      Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Tapan-Kadia
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX
11:50 AM      Optimising Post-Transplant Outcomes in Acute Myeloid Leukemia: the ACT Platform for Transplant Trial Delivery
Charlie-Craddock
Charlie Craddock, MD
Queen Elizabeth Hospital Birmingham, UK
12:05 PM      Panel Discussion
12:35 PM      Industry Supported Independent Expert Discussion
01:20 PM      Lunch & Networking

Session IX: Management of Rare and New Entities and Novel Strategies
Moderated by:

Lori-Muffly

Lori Muffly, MD
Stanford Medicine, CA

 

02:10 PM      Therapy Related Myeloid Neoplasms After ALL Therapy?
Koichi_Takahashi
Koichi Takahashi, MD
MD Anderson Cancer Center, Houston, TX
02:25 PM      BH3 Mimetics in ALL
Daniel-Deangelo
Daniel J. DeAngelo, MD
Dana-Farber Cancer Institute, Boston, MA
02:40 PM      CAR T-cells of T-ALL
Armin-Ghobadi-1
Armin Ghobadi, MD
Washington University School of Medicine, St. Louis, MO
02:55 PM      MPAL Management
Jayastu-Senapati
Jayastu Senapati, MD
MD Anderson Cancer Center, Houston, TX
03:10 PM      Panel Discussion
03:40 PM      Coffee Break & Networking

Session X: Antibody Based Therapies and Optimizing Dosing of VEN in AML
Moderated by:

Charlie-Craddock

Charlie Craddock, MD
Queen Elizabeth Hospital Birmingham, UK

 

04:00 PM      Developing CARTs in AML: Current Status, Challenges, Emerging Constructs and Future Directions
Jae-Park
Jae Park, MD
Memorial Sloan Kettering Cancer Center,
New York, NY
04:15 PM      CD33 and CD123 ADCs in AML: From GO to CD123 – Has the Path Been Paved?
Farhad-Ravandi
Farhad Ravandi, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM      Optimal Dose of VEN in Frontline HMAVEN and Implications for Future Triplets/Combos
Uma-Borate
Uma Borate, MD
The Ohio State University, Ohio
04:45 PM      Panel Discussion & Take-home Points
05:15 PM      Adjourn

Rebecca Hill
Project Manager

How long has Rebecca Hill been in the business?

Rebecca Hill has been with MD Education since 2022

About Rebecca Hill

I am a dedicated Senior Project Manager at MD Education, specialising in coordinating global medical conferences. I have a passion for organisation and detail, and I pride myself on ensuring seamless execution of educational events. My expertise lies in orchestrating logistics and fostering collaboration among diverse teams.

Rebecca-Hill